These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39120850)

  • 1. Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V
    Rheumatol Ther; 2024 Oct; 11(5):1081-1084. PubMed ID: 39120850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V; Bender S; McCabe D
    Rheumatol Ther; 2024 Oct; 11(5):1291-1302. PubMed ID: 39120847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
    Cohen SB; Lee EC
    Immunotherapy; 2022 Oct; 14(15):1183-1190. PubMed ID: 36065786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
    Menter A
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2929-2932. PubMed ID: 37875714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.
    Bhat S; Patel M; Duly K; Choi D
    Ann Pharmacother; 2022 Dec; 56(12):1356-1364. PubMed ID: 35392668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
    Cohen SB; Czeloth N; Lee E; Klimiuk PA; Peter N; Jayadeva G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1097-1105. PubMed ID: 31387417
    [No Abstract]   [Full Text] [Related]  

  • 8. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
    Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
    Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF).
    Moschetti V; Buschke S; Bertulis J; Hohl K; McCabe D
    Expert Opin Biol Ther; 2024 Jul; 24(7):673-679. PubMed ID: 38739422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
    Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
    Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals.
    Perez R; Suman JD; Reynolds J
    Expert Opin Drug Deliv; 2024 Aug; ():. PubMed ID: 39192830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM
    Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
    Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.
    Edwards CJ; Monnet J; Ullmann M; Vlachos P; Chyrok V; Ghori V
    Clin Rheumatol; 2019 Dec; 38(12):3381-3390. PubMed ID: 31396834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
    Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease.
    Hanauer S
    Immunotherapy; 2022 Dec; 14(17):1353-1359. PubMed ID: 36511191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
    Huizinga TWJ; Torii Y; Muniz R
    Rheumatol Ther; 2021 Mar; 8(1):41-61. PubMed ID: 33263165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.
    Fleischmann RM; Saikali W; Lakhanpal S; Alvarez DF; Cox DS; Ianos CA; Zhang W; Cronenberger C; Wang K
    Lancet Rheumatol; 2023 Sep; 5(9):e532-e541. PubMed ID: 38251497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.